We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Study Comparing Acne in Patients Taking Oral Minocycline to Patients Taking Minocycline Plus Topical Tretinoin

This study has been terminated.
(Too much difficulty recruiting and retaining patients, PI decided to stop.)
ClinicalTrials.gov Identifier:
First Posted: October 18, 2005
Last Update Posted: February 24, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Stiefel, a GSK Company
Information provided by (Responsible Party):
David Richard THOMAS, Derm Research @ 888 Inc.

The use of oral antibiotics alone to treat inflammatory acne provides little to no long term therapeutic benefit.

Acne relapse rates can be reduced by using topical tretinoin 0.01% in conjunction with minocycline, thereby increasing the therapeutic effect of the oral antibiotic.

Condition Intervention Phase
Acne Vulgaris Drug: Minocycline Drug: Minocycline plus tretinoin Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Investigator)
Primary Purpose: Treatment
Official Title: A Randomized Study to Compare the Acne Relapse Rate After a 3-mo Course of Oral Minocycline, to a 3-mo Course of Oral Minocycline in Combination With a Daily Dose of Topical Tretinoin 0.01% Followed by 3 mo of Topical Tretinoin Alone

Resource links provided by NLM:

Further study details as provided by David Richard THOMAS, Derm Research @ 888 Inc.:

Primary Outcome Measures:
  • Long-term efficacy [ Time Frame: 4 years ]

Secondary Outcome Measures:
  • Relapse rate [ Time Frame: 4 years ]

Enrollment: 38
Study Start Date: August 2004
Study Completion Date: December 2006
Primary Completion Date: December 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Minocycline 3 mo
Minocycline 3 mo
Drug: Minocycline
100 mg capsules OD for 3 months
Other Name: Minocin
Experimental: Minocycline plus Tretinoin
Minocycline plus Tretinoin for 3 months
Drug: Minocycline plus tretinoin
100mg OD Minocycline for 12 weeks plus OD Topical tretinoin 0.01% for 12 weeks Followed by topical tretinoin 0.01% OD for 12 weeks alone
Other Names:
  • Minocin
  • Tretinoin

Detailed Description:

Although oral antibiotics have been the mainstay of treatment of inflammatory acne for 30 years, studies comparing their efficacy have little scientific value.

Evidence-based dermatology proves minocycline to be an effective treatment for acne vulgaris while the patient remains on the medication; however, the relapse rate of acne after a course of antibiotics has never been established.

The relapse rate would appear to be significant, as repeated courses and long-term antibiotic use are commonly prescribed in practice. The increasing problem of drug resistance has raised issues of the suitability of such long term antibiotic treatment and this overuse is probably a contributing factor of multiple drug resistance in our society.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Provision of written consent
  • Either sex
  • Any age
  • Diagnosis of acne vulgaris with a minimum of 20 inflammatory acne lesions on the face.

Exclusion Criteria:

  • Known hypersensitivity to tetracyclines
  • Use of any oral antibiotics in the previous 3 months
  • Pregnancy, breast-feeding or lactating
  • Inability or unwillingness to comply with the requirements of the protocol, or agree to the use of their data as determined by the investigator.
  • Concomitant medical condition which, in the investigator's opinion, may confound the study results or interfere with study assessments or outcomes.
  • Patients with severe acne on the chest, back or trunk.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00240513

Canada, British Columbia
Derm Research @ 888 Inc
Vancouver, British Columbia, Canada, V5Z 3Y1
Sponsors and Collaborators
Derm Research @ 888 Inc.
Stiefel, a GSK Company
Principal Investigator: Richard Thomas, MD, FRCP(C) DermResearch @ 888 Inc.
  More Information

Responsible Party: David Richard THOMAS, MD FRCP(C), Derm Research @ 888 Inc.
ClinicalTrials.gov Identifier: NCT00240513     History of Changes
Other Study ID Numbers: 2004-03
First Submitted: October 16, 2005
First Posted: October 18, 2005
Last Update Posted: February 24, 2012
Last Verified: February 2012

Keywords provided by David Richard THOMAS, Derm Research @ 888 Inc.:

Additional relevant MeSH terms:
Acne Vulgaris
Acneiform Eruptions
Skin Diseases
Sebaceous Gland Diseases
Anti-Bacterial Agents
Anti-Infective Agents
Antineoplastic Agents
Keratolytic Agents
Dermatologic Agents